Thalidomide-Cyclophosphamide-Dexamethasone in Patients < 75 Years or Velcade-Melfalan-Prednisone (V-MP)/Thalidomide-Cyclophosphamide-Dexamethasone in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma
Multicentric study, open, single arm, designed to evaluate the efficacy(response rate and
response duration) and security of a sequential scheme of treatment with Bortezomib in
combination with Melfalan and Prednisone (V-MP) (patients > 75 years) or Bortezomib and
Adriamycine in combination with Melfalan and Prednisone (VAMP) (patients <= 75 years) follow
by Thalidomide in combination with Cyclophosphamide and Dexamethasone (TaCyDex) in patients
with refractary or relapse multiple myeloma.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Efficacy of a sequential scheme treatment with Bortezomib, Melfalan,Prednisone (V-MP) or Bortezomib, Adriamycine, Melfalan,Prednisone (VAMP) followed by Thalidomide, Cyclophosphamide and Dexamethasone (TaCyDex) in relapsed or refractory MM patients
1 year
No
Spain: Ministry of Health
TaCyDexVMP7
NCT00652041
January 2007
June 2010
Name | Location |
---|